Forian (NASDAQ:FORA) Earns “Buy” Rating from Roth Mkm

Forian (NASDAQ:FORAGet Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at Roth Mkm in a research report issued to clients and investors on Thursday,Benzinga reports. They currently have a $5.00 target price on the stock. Roth Mkm’s price objective indicates a potential upside of 150.00% from the stock’s current price.

Forian Price Performance

NASDAQ:FORA opened at $2.00 on Thursday. Forian has a 1 year low of $1.99 and a 1 year high of $4.15. The stock’s fifty day moving average price is $2.13 and its two-hundred day moving average price is $2.43. The company has a market cap of $62.22 million, a P/E ratio of -22.22 and a beta of 1.09.

Forian (NASDAQ:FORAGet Free Report) last issued its earnings results on Wednesday, August 14th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.06). The business had revenue of $4.78 million during the quarter, compared to analyst estimates of $5.26 million. During the same period in the prior year, the company posted ($0.03) EPS.

Hedge Funds Weigh In On Forian

Hedge funds have recently bought and sold shares of the company. Elser Financial Planning Inc purchased a new position in shares of Forian during the 2nd quarter valued at $1,885,000. Caprock Group LLC bought a new stake in Forian during the second quarter valued at $230,000. Finally, Canton Hathaway LLC grew its position in Forian by 2.3% during the third quarter. Canton Hathaway LLC now owns 269,650 shares of the company’s stock worth $582,000 after buying an additional 6,125 shares in the last quarter. Hedge funds and other institutional investors own 19.25% of the company’s stock.

Forian Company Profile

(Get Free Report)

Forian Inc provides a suite of data management capabilities, and information and analytics solutions to optimize and measure operational, clinical, and financial performance for customers in the healthcare and related industries. It develops commercial, real world evidence (RWE), and market access solutions and proprietary data-driven insights, as well as offers data management solutions.

Read More

Receive News & Ratings for Forian Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forian and related companies with MarketBeat.com's FREE daily email newsletter.